EUROSTARS PROJECT > 7090 Foxy-5

Development of Foxy-5 as a first in class anti-metastatic cancer drug

Foxy-5 is a small peptide that mimics the effects of the protein Wnt-5a. Foxy-5 inhibits the development of metastasis and thereby increase survival rates in patients with breast and in particular colorectal cancer. Tumour metastasis is the predominant cause of death among cancer patients.

Status > Approved - 01-Mar-2012

Call > 7

Cost > 6098364.0 €

Duration > 35 Months

Market > Therapeutic

Technology > Medical technology